KEYNOTE-A39/EV-302 Presentation

KEYTRUDA® (pembrolizumab), in combination with enfortumab vedotin▼, is indicated for the first-line treatment of unresectable or metastatic urothelial carcinoma in adults.

Prescribing Information [External link]

Please refer to the KEYTRUDA Summary of Product Characteristics and Risk Minimisation Materials before prescribing KEYTRUDA. Risk Minimisation Materials are available online, from your MSD representative or from MSD Medical Information (Email: medicalinformationuk@msd.com, Phone: 0208 154 8000).